AIN457 + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Non-infectious Uveitis

Conditions

Non-infectious Uveitis

Trial Timeline

Aug 1, 2010 → Jul 1, 2011

NCT ID

NCT01090310

About AIN457 + Placebo

AIN457 + Placebo is a phase 3 stage product being developed by Novartis for Non-infectious Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01090310. Target conditions include Non-infectious Uveitis.

What happened to similar drugs?

2 of 6 similar drugs in Non-infectious Uveitis were approved

Approved (2) Terminated (1) Active (3)

✅AdalimumabAbbVieApproved

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

❌AIN457 + AIN457 + AIN457 + PlaceboNovartisPhase 3

🔄FAI insert + Sham injectionEyePoint PharmaceuticalsPhase 3

🔄FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserterEyePoint PharmaceuticalsPhase 3

🔄ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic SolutionAldeyra TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01090310	Phase 3	Terminated	Aug 1, 2010	Jul 1, 2011	Non-infectious Uveitis
NCT01132612	Phase 2	Completed	May 11, 2010	Oct 18, 2016	Plaque-type Psoriasis
NCT01071252	Phase 2	Completed	Mar 1, 2010	Feb 1, 2011	Chronic Plaque-type Psoriasis
NCT01051817	Phase 2	Completed	Dec 1, 2009	Apr 1, 2012	Relapsing-remitting Multiple Sclerosis
NCT00809614	Phase 2	Completed	Mar 1, 2009	Dec 1, 2010	Psoriatic Arthritis
NCT00809159	Phase 2	Completed	Mar 1, 2009	May 1, 2011	Ankylosing Spondylitis
NCT00805480	Phase 2	Completed	Dec 1, 2008	Sep 1, 2010	Chronic Plaque Psoriasis
NCT00770965	Phase 2	Completed	Sep 10, 2008	Sep 17, 2009	Chronic Plaque Psoriasis
NCT00584740	Phase 2	Terminated	Aug 1, 2008	Aug 1, 2010	Crohn's Disease
NCT00669916	Phase 1/2	Completed	Feb 1, 2007	Nov 1, 2007	Plaque Psoriasis
NCT00669942	Phase 1/2	Completed	Dec 1, 2005	Nov 1, 2008	Rheumatoid Arthritis

Competing Products

10 competing products in Non-infectious Uveitis

See all competitors

Product	Company	Stage	Hype Score
Adalimumab	AbbVie	Approved	43
LFG316 + Conventional Therapy	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
ESK-001	Alumis	Phase 2	21
Topical Prednisolone Acetate 1%	Ocular Therapeutix	Approved	33
FAI insert + Sham injection	EyePoint Pharmaceuticals	Phase 3	34
FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter	EyePoint Pharmaceuticals	Phase 3	34
ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution	Aldeyra Therapeutics	Phase 3	30
NS2 + Prednisolone acetate ophthalmic suspension (1%)	Aldeyra Therapeutics	Phase 2	25